Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma Group (MREO) Prepaid Assets: 2020-2025

Historic Prepaid Assets for Mereo BioPharma Group (MREO) over the last 2 years, with Sep 2025 value amounting to $2.7 million.

  • Mereo BioPharma Group's Prepaid Assets fell 29.66% to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.7 million, marking a year-over-year decrease of 29.66%. This contributed to the annual value of $2.2 million for FY2024, which is 57.82% down from last year.
  • According to the latest figures from Q3 2025, Mereo BioPharma Group's Prepaid Assets is $2.7 million, which was up 5.85% from $2.5 million recorded in Q2 2025.
  • Mereo BioPharma Group's 5-year Prepaid Assets high stood at $6.2 million for Q2 2021, and its period low was $2.2 million during Q4 2024.
  • Over the past 3 years, Mereo BioPharma Group's median Prepaid Assets value was $2.9 million (recorded in 2024), while the average stood at $3.3 million.
  • As far as peak fluctuations go, Mereo BioPharma Group's Prepaid Assets surged by 255.39% in 2021, and later plummeted by 57.82% in 2024.
  • Over the past 5 years, Mereo BioPharma Group's Prepaid Assets (Quarterly) stood at $3.8 million in 2021, then skyrocketed by 44.34% to $5.4 million in 2022, then declined by 5.33% to $5.2 million in 2023, then slumped by 57.82% to $2.2 million in 2024, then dropped by 29.66% to $2.7 million in 2025.
  • Its Prepaid Assets was $2.7 million in Q3 2025, compared to $2.5 million in Q2 2025 and $2.5 million in Q1 2025.